Dapagliflozin Ameliorates the Formation and Progression of Experimental Abdominal Aortic Aneurysms by Reducing Aortic Inflammation in Mice

Figure 1

Dapagliflozin treatment suppresses experimental AAAs. (a) Study design: male C57BL/6 mice were given dapagliflozin (1 or 5 mg/kg body weigh) or vehicle by gavage for 14 days ( mice/group). (b) Mean and SD of aortic diameters at the baseline level (day 0) and 14 days after PPE infusion. Dotted line: the average aortic diameter following PBS infusion (0.8 mm). Two-way ANOVA followed by two group comparison, and between two groups. (c) Representative abdominal aortic images at the baseline (day 0) and 14 days after PPE infusion. (d) Change in aortic diameter (percent increase over the baseline level). One-way ANOVA followed by two group comparison, between two groups. DAPA: dapagliflozin.

(a)

(b)

(c)

(d)